177 related articles for article (PubMed ID: 21624454)
1. The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain.
Manning SM; Boll G; Fitzgerald E; Selip DB; Volpe JJ; Jensen FE
Int J Dev Neurosci; 2011 Nov; 29(7):767-73. PubMed ID: 21624454
[TBL] [Abstract][Full Text] [Related]
2. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia.
Manning SM; Talos DM; Zhou C; Selip DB; Park HK; Park CJ; Volpe JJ; Jensen FE
J Neurosci; 2008 Jun; 28(26):6670-8. PubMed ID: 18579741
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury.
Liu C; Lin N; Wu B; Qiu Y
Brain Res; 2009 Jul; 1282():173-82. PubMed ID: 19501064
[TBL] [Abstract][Full Text] [Related]
4. Delayed preconditioning with NMDA receptor antagonists in a rat model of perinatal asphyxia.
Makarewicz D; Sulejczak D; Duszczyk M; Małek M; Słomka M; Lazarewicz JW
Folia Neuropathol; 2014; 52(3):270-84. PubMed ID: 25310738
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
[TBL] [Abstract][Full Text] [Related]
6. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.
Rammes G; Mahal B; Putzke J; Parsons C; Spielmanns P; Pestel E; Spanagel R; Zieglgänsberger W; Schadrack J
Neuropharmacology; 2001 May; 40(6):749-60. PubMed ID: 11369029
[TBL] [Abstract][Full Text] [Related]
7. Treatment with UDP-glucose, GDNF, and memantine promotes SVZ and white matter self-repair by endogenous glial progenitor cells in neonatal rats with ischemic PVL.
Li WJ; Mao FX; Chen HJ; Qian LH; Buzby JS
Neuroscience; 2015 Jan; 284():444-458. PubMed ID: 25453769
[TBL] [Abstract][Full Text] [Related]
8. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells.
Bresink I; Benke TA; Collett VJ; Seal AJ; Parsons CG; Henley JM; Collingridge GL
Br J Pharmacol; 1996 Sep; 119(2):195-204. PubMed ID: 8886398
[TBL] [Abstract][Full Text] [Related]
9. 1-Deoxysphingolipid-induced neurotoxicity involves N-methyl-d-aspartate receptor signaling.
Güntert T; Hänggi P; Othman A; Suriyanarayanan S; Sonda S; Zuellig RA; Hornemann T; Ogunshola OO
Neuropharmacology; 2016 Nov; 110(Pt A):211-222. PubMed ID: 27016021
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
11. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
12. Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells.
Affaticati P; Mignen O; Jambou F; Potier MC; Klingel-Schmitt I; Degrouard J; Peineau S; Gouadon E; Collingridge GL; Liblau R; Capiod T; Cohen-Kaminsky S
Cell Death Differ; 2011 Jan; 18(1):99-108. PubMed ID: 20577261
[TBL] [Abstract][Full Text] [Related]
13. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.
Wenk GL; Danysz W; Mobley SL
Eur J Pharmacol; 1995 Oct; 293(3):267-70. PubMed ID: 8666045
[TBL] [Abstract][Full Text] [Related]
14. Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter.
Bakiri Y; Hamilton NB; Káradóttir R; Attwell D
Glia; 2008 Jan; 56(2):233-40. PubMed ID: 18046734
[TBL] [Abstract][Full Text] [Related]
15. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease.
Motawaj M; Burban A; Davenas E; Arrang JM
J Pharmacol Exp Ther; 2011 Feb; 336(2):479-87. PubMed ID: 21057059
[TBL] [Abstract][Full Text] [Related]
16. [Memantine: a therapeutic drug for Alzheimer's disease and the comparison with MK-801].
Kato T
Nihon Yakurigaku Zasshi; 2004 Sep; 124(3):145-51. PubMed ID: 15333987
[TBL] [Abstract][Full Text] [Related]
17. Delayed white matter injury in a murine model of shaken baby syndrome.
Bonnier C; Mesplès B; Carpentier S; Henin D; Gressens P
Brain Pathol; 2002 Jul; 12(3):320-8. PubMed ID: 12146800
[TBL] [Abstract][Full Text] [Related]
18. Memantine improves outcomes after repetitive traumatic brain injury.
Mei Z; Qiu J; Alcon S; Hashim J; Rotenberg A; Sun Y; Meehan WP; Mannix R
Behav Brain Res; 2018 Mar; 340():195-204. PubMed ID: 28412305
[TBL] [Abstract][Full Text] [Related]
19. MK-801 and memantine act differently on short-term memory tested with different time-intervals in the Morris water maze test.
Duda W; Wesierska M; Ostaszewski P; Vales K; Nekovarova T; Stuchlik A
Behav Brain Res; 2016 Sep; 311():15-23. PubMed ID: 27180167
[TBL] [Abstract][Full Text] [Related]
20. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis.
de Bartolomeis A; Sarappa C; Buonaguro EF; Marmo F; Eramo A; Tomasetti C; Iasevoli F
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():1-12. PubMed ID: 23800465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
